biostudies-literatureGarcia-Borreguero DIntramural NIH HHS2387-2392https://www.ebi.ac.uk/biostudies/studies/S-EPMC8530834biostudies-literatureUnknown36(10)<h4>Background</h4>New pharmacological targets are needed for restless legs syndrome. Preclinical data suggest that a hypoadenosinergic state plays an important pathogenetic role.<h4>Objective</h4>The objective of this study was to determine whether inhibitors of equilibrative nucleoside transporters, for example, dipyridamole, could provide effective symptomatic treatment.<h4>Methods</h4>A 2-week double-blind, placebo-controlled crossover study assessed the efficacy of dipyridamole (possible up-titration to 300 mg) in untreated patients with idiopathic restless legs syndrome. Multiple suggested immobilization tests and polysomnography were performed after each treatment phase. Severity was assessed weekly using the International Restless Legs Rating Scale, Clinical Global Impression, and Movement disorders : official journal of the Movement Disorder SocietyA Randomized, Placebo-Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome.PMC8530834Z99 DA999999Ferre SGranizo JJGarcia-Borreguero DGarcia-Malo CfalseA Randomized, Placebo-Controlled Crossover Study with Dipyridamole for Restless Legs Syndrome.<h4>Background</h4>New pharmacological targets are needed for restless legs syndrome. Preclinical data suggest that a hypoadenosinergic state plays an important pathogenetic role.<h4>Objective</h4>The objective of this study was to determine whether inhibitors of equilibrative nucleoside transporters, for example, dipyridamole, could provide effective symptomatic treatment.<h4>Methods</h4>A 2-week double-blind, placebo-controlled crossover study assessed the efficacy of dipyridamole (possible up-titration to 300 mg) in untreated patients with idiopathic restless legs syndrome. Multiple suggested immobilization tests and polysomnography were performed after each treatment phase. Severity was assessed weekly using the International Restless Legs Rating Scale, Clinical Global Impression, and 2021-01-01T00:00:00Z2021 Oct2025-04-21T18:55:33.317Z2025-04-05T17:26:47.217ZS-EPMC85308343413747610.1002/mds.28668